Obesity Abstracts

Aims: Liraglutide 3 mg once daily is an approved, prescription injectable Glucagon Like Peptide-1 receptor agonist that, when used with a low-calorie diet and increased physical activity, can reduce excess weight in patients with obesity. MiRNAs are small non-coding single stranded RNAs that regulate gene expression post-transcriptionally by inhibiting their mRNA target translation into proteins. MiRNAs can be secreted in the blood stream and affect the molecular pathways of d...

Liraglutide 3 mg daily is an approved, prescription injectable GLP-1 receptor agonist, which can reduce weight in patients with obesity, with or without obesity complications. We conducted a 24-week, open-label real-world study involving 62 participants with a BMI >30 kg/m2 or >27 kg/m2 if they had co-existing dyslipidaemia or hypertension. No patients had type 2 diabetes. Patients received once-daily subcutaneous liraglutide 3.0 mg, alongside NHS...